Conversations in Drug Development Trends

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. ADCs are continually evolving, bringing forward new targets across various cancer types, including rare and orphan cancers.

Clinical Trials 64

Clinical Trials Therapies Clinical Research Immune Response 64

Advarra

JUNE 12, 2023

Gene therapy research is exciting and full of promise, but because of the risks involved, it’s also highly regulated, requiring an institutional biosafety committee (IBC) to provide additional oversight and risk assessment.

Engineering 98

Engineering Therapies Regulations Research 98

Broad Institute

DECEMBER 11, 2024

If you have DNA from blood or another tissue that hasnt been affected by cancer, you can compare normal and tumor tissue and you can tell: these mutations are not cancer-related but these ones are. In clinical research, are we recruiting a diverse community of patients into our studies so that our findings translate to diverse communities?

Research 105

Research DNA Clinical Research Science 105

Broad Institute

AUGUST 24, 2022

The research team used an innovative analytic approach that they previously developed called microscaled proteogenomics to analyze tumor biopsies taken from TNBC patients prior to treatment with carboplatin and docetaxel combination chemotherapy. These data suggest a multi-omics predictor for chemotherapy response is within reach.

DNA 52

DNA Protein Expression Treatment Protein Production 52

The Pharma Data

OCTOBER 18, 2020

(NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at the effect of nicotinamide riboside (NR) on maintaining telomeres, the protective regions at the end of DNA strands. Telomeres are “caps” at the end of chromosomes that protect DNA from getting worn away as cells replicate.

DNA 52

DNA Molecular Biology Disease Trials 52

Drug Target Review

JUNE 6, 2023

Increasingly, IO researchers and biotech R&D teams are prioritising localised IL-12 delivery mechanisms that target tumours directly. Our deep interest in the interplay between immune cells, cytokines, and the tumour microenvironment has informed our clinical research to date as well as our IO pipeline program.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Vial

DECEMBER 5, 2023

Transforming Genomics Research Next-generation sequencing (NGS) enables comprehensive genome sequencing and has transformed genomics research, offering vastly improved capabilities for analyzing DNA and RNA in a high-throughput and cost-effective manner. Satam et al.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

The Pharma Data

JUNE 24, 2021

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).

Clinical Trials 52

Clinical Trials DNA Trials Treatment 52

Advarra

MARCH 31, 2023

Among the various regulatory bodies providing oversight on clinical research, only the institutional biosafety committee (IBC) has a purview specific to research involving engineered genetic materials. The post Risk Assessment for use of Engineered Genetic Materials in Clinical Research appeared first on Advarra.

Engineering 52

Engineering Clinical Research Research Virus 52

Creative Biolabs

MAY 25, 2022

These cytotoxic drugs include DNA base analogs, antimetabolic drugs, tubulin inhibitors, etc. Fu, 2022) Clinical research progress of ADC After decades of efforts, more than 100 ADCs are currently under clinical development. For decades, cytotoxic-based chemotherapy has been the main treatment for all kinds of cancers.

Therapies 52

Therapies Drugs DNA Treatment 52

The Pharma Data

OCTOBER 14, 2020

The new services have been developed to support pre-clinical research by optimizing hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models. Axol Bioscience – Based in the U.K.,

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Therapies 52

Advarra

AUGUST 10, 2023

However, recent advancements in the clinical use of recombinant DNA (rDNA) technology creates opportunities for changing this calculation and addressing a great, unmet medical need. “I The project should also help clinical research sponsors take advantage of various FDA pathways for accelerated review and approval.

Drug Development 52

Drug Development Disease Therapies Engineering 52

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. Synthetic mRNA-based therapeutics used in clinical research today also fall into this self-limiting class of recombinant therapeutics.

Clinical Trials 52

Clinical Trials Engineering Trials Virus 52

The Anticancer Fund

APRIL 1, 2022

Using both mice models and patient-derived tumour organoids and primary stroma cells, this study shows that interleukin-1a(IL-1a) polarises cancer-associated fibroblasts toward the inflammatory phenotype but also triggers oxidative DNA damage which in turn leads to stromal cell senescence in response to radiation.

Clinical Trials 40

Clinical Trials Drugs Trials Pharmacokinetics 40

The Pharma Data

MARCH 9, 2021

Lenacapavir is a potential first-in-class capsid inhibitor that is designed to inhibit HIV replication as it interferes with the disassembly of the HIV capsid core, inhibits the role of capsid proteins during viral RNA/DNA translocation to the nucleus, and disrupts assembly of the capsid core.

Treatment 52

Treatment RNA Trials Science 52

Agency IQ

FEBRUARY 2, 2024

Although the guideline notes that collecting tumor tissue in progressive disease is important, the authors also address collection of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) as approaches “that allow easy and repeated sampling.”

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40

Codon

JULY 21, 2024

And whereas it used to be costly for breeders to select for traits beyond the needs of their industry, the falling costs of advanced genomic selection techniques—breeding using DNA sequence data—make it increasingly fast and feasible. As complicated biological creatures, we require complicated biological models.

Research 122

Research Engineering Disease Science 122

Drug Target Review

DECEMBER 13, 2024

Innovations in payload substances, such as topoisomerase inhibitors (topo-1i), and next-generation DNA- damaging agents to replace older, more toxic agents. 7 Recent clinical studies highlight promising developments in c-MET-targeting ADCs for NSCLC. MET alterations in advanced non-small cell lung cancer. Curr Probl Cancer.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

Drug Target Review

MARCH 25, 2025

The convergence of advanced research tools, a growing understanding of tumour biology, and urgent unmet patient needs makes this the perfect moment to reignite focus on DNA Damage Response in cancer therapy. Exploring these combinations may provide new avenues for overcoming resistance and improving treatment precision.

DNA 52

DNA Therapies Clinical Trials Clinical Pharmacology 52

Codon

APRIL 24, 2025

We’re close to selling out of our second book —written in both text and DNA—and we recently launched a merchandise store. You can check them out via our website.

Clinical Trials 100

Clinical Trials Trials Pharmaceutical Companies Licensing 100

PPD

MARCH 28, 2025

Oligonucleotides, also known as oligos, are strands of artificially created DNA or RNA that are instrumental in numerous molecular and synthetic biology applications. These applications range from genetic testing and forensic research to next-generation sequencing (NGS).

Laboratories 52

Laboratories Production International RNA 52

Drug Target Review

JANUARY 20, 2025

This approach aims to improve treatment efficacy (compared to cytotoxic chemotherapy), minimise toxicity, and necessitates an evolution in clinical trial methodologies. Genetic factors Mutations or alterations in tumour DNA (eg, EGFR mutations in lung cancer or HER2 amplification in breast cancer) are key targets of precision medicine.

Clinical Trials 52

Clinical Trials Trials Drugs Drug Development 52

The Pharma Data

DECEMBER 20, 2020

eTrueNorth is actively recruiting COVID-19-positive patients about potential participation in the NIH’s ACTIV-2 clinical research trial. The data demonstrated the vaccine elicited a combined adaptive humoral and cellular immune response and also provided insights into the composite nature of BNT162b2-induced T-cell immunity.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

Conversations in Drug Development Trends

APRIL 7, 2025

Solid tumors present a significant challenge to clinical research due to their complex and heterogeneous nature. Proactively Address Key Recruitment Challenges in Solid Tumor Clinical Research Solid tumor clinical research is challenging, especially because of tumor heterogeneity.

Research 40

Research Clinical Trials Trials Clinical Research 40

NIH Director's Blog: Drug Development

JANUARY 5, 2016

The RNA is preprogrammed to find a distinct short sequence of DNA and deliver the enzyme, which acts like a scalpel to slice the sequence out of the genome. The NIAID investigators also took part in the preclinical development of the vaccine and in Phase II clinical trials in Liberia. It’s fast and pretty precise.

Vaccine 52

Vaccine Science Disease Engineering 52

Codon

OCTOBER 27, 2024

Archaeologists have found evidence of ancient Egyptian mummies carrying the pathogen’s DNA , including some that had developed Pott’s disease — a bending of the spine brought on by TB spreading to bones. The current lineage of M. tuberculosis has plagued our species for 15 to 20 thousand years.

Immune Response 99

Immune Response Doctors Disease Laboratories 99